APA (7th ed.) Citation

Cui, C., Cao, F., Kong, I. I., Wu, Q., Li, F., Li, H., & Liu, D. (2024). A model‐informed approach to accelerate the clinical development of cofrogliptin (HSK7653), a novel ultralong‐acting dipeptidyl peptidase‐4 inhibitor. Diabetes, obesity & metabolism, 26(2), 592-601. https://doi.org/10.1111/dom.15348

Chicago Style (17th ed.) Citation

Cui, Cheng, Fangrui Cao, Iok Ian Kong, Qinghe Wu, Fangqiong Li, Haiyan Li, and Dongyang Liu. "A Model‐informed Approach to Accelerate the Clinical Development of Cofrogliptin (HSK7653), a Novel Ultralong‐acting Dipeptidyl Peptidase‐4 Inhibitor." Diabetes, Obesity & Metabolism 26, no. 2 (2024): 592-601. https://doi.org/10.1111/dom.15348.

MLA (9th ed.) Citation

Cui, Cheng, et al. "A Model‐informed Approach to Accelerate the Clinical Development of Cofrogliptin (HSK7653), a Novel Ultralong‐acting Dipeptidyl Peptidase‐4 Inhibitor." Diabetes, Obesity & Metabolism, vol. 26, no. 2, 2024, pp. 592-601, https://doi.org/10.1111/dom.15348.